Rani Therapeutics Holdings, Inc. — Cyborg Score 4/10
Mixed
Biopharmaceutical Drug Delivery
Strategic Profile
Rani is advancing a Phase 1 clinical trial evaluating RT-114 for obesity treatment in collaboration with ProGen. The company is in early-stage development with losses narrowing year-over-year, and recently secured capital through an at-the-market offering in May 2026 to extend runway and evaluate pipeline opportunities.
Cyborg Score Rationale
Early-stage clinical company with innovative platform technology and improving financial trajectory, but facing near-term challenges including Nasdaq listing compliance concerns (stock price below $1.00 as of May 2026) and a small cash base requiring capital raises to fund development.
Top Insights
(May 2026) Secured $20 million direct offering led by sovereign wealth fund at $1.07/share to fund ongoing clinical work and portfolio evaluation
(Q1 2026) Net losses declining to $8.0M from $12.7M YoY; company achieved improved operational efficiency despite clinical stage development
(May 2026) Nasdaq compliance issues: stock bid price below $1.00 minimum for 30 consecutive trading days; company has grace period to regain compliance
(May 2026) Strategic leadership additions with new Head of Strategy and Scientific Advisors to evaluate RaniPill® platform opportunities beyond obesity
Named Competitors
GLP-1 Receptor Agonists — Leading injectable obesity treatment (Ozempic, Wegovy)